NCT02370758View on ClinicalTrials.gov

Cell Mediated Immunity for Secondary Prophylaxis in CMV SOT Patients

NACompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

September 30, 2016

Study Completion Date

June 16, 2017

Conditions
Cytomegalovirus Viraemia
Interventions
DRUG

Valganciclovir or Ganciclovir

Trial Locations (1)

M5G2N2

University Health Network, Toronto General Hospital, Multi-Organ Transplant, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT02370758 - Cell Mediated Immunity for Secondary Prophylaxis in CMV SOT Patients | Biotech Hunter | Biotech Hunter